Foothill Ranch, CA (PRWEB) December 15, 2005
The global diabetes market is an aggregate of drugs/medications, devices, diagnostics, therapeutics and their combinations. Medications segment into insulins and orally-taken drugs; the insulin market now consists almost entirely of human insulins. The orally active drugs segment is comprised of multiple drug classes, with older categories losing market share to newcomers, and while the diabetes medication market has previously been slow to adopt new formulations, this is rapidly changing.
Markets for glucose monitoring devices and insulin delivery devices demonstrate diverse rates of market growth across different geographic sectors, based on technology penetration and changes in diabetes prevalence, with the forecast for continued changes to the market. Monitoring devices consist almost entirely of glucose monitors, although other forms of testing (e.g., HbA1c testing for measure of long term glucose control) are growing in importance. The monitor market is made up of blood sampling devices and meters which automate the process of calculating glucose level and insulin dosage. Minimally- and non-invasive sampling devices are realizing greater shares as the technologies are now achieving their potential in solving the need for relatively pain-free sampling.
The 2005 MedMarket Diligence report on wound management details the current and emerging technologies and products in the management of type 1 and type 2 diabetes, with products spanning drugs/medications, devices, diagnostics and therapeutics. Detailed country and region-specific data is provided on forecast market size and competitor market shares in the U.S., Japan, and major European countries. The report, "Diabetes Management Market, Worldwide, 2005-2015," is described at http://www.mediligence.com/rpt-d500.htm.
MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries. The company publishes the MedMarkets newsletter, a monthly analysis of the market implications of new medical technologies, and dedicated reports on technology markets. For additional details, contact Patrick Driscoll at email or call 949-859-3401 or toll-free (in the U.S.). 1-866-820-1357.